Accelerating and diversifying clinical trial participation is necessary for improving the efficiency and representativeness of cancer clinical research. Slow accrual wastes resources and hinders the translation of scientific innovation into patient gains. Inequities in enrollment prohibit access to novel therapeutics to underrepresented groups and impairs the evidence basis for shared decision-making. Historically, there have been several proposals aimed to ameliorate these problems. The National Institutes of Health (NIH) Revitalization Act of 1993 was the first federal attempt to reduce disparities by mandating that NIH-funded research studies increase the enrollment of women and members of racial and ethnic minority groups and report subgroup analyses.
1 Furthermore, research indicates that outcomes of pivotal cancer clinical trials do not adequately reflect those of older adults treated in the general population.
2